Helius Medical Technologies Inc (HSDT)

Overview News Price History Why HSDT Down? Discussions Forecast Stock Split

Helius Medical Technologies Inc stock is currently priced at $5.145, with a 24-hour trading volume of 4,495. It has seen a +0.68% increased in the last 24 hours and a -9.26% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $5.13 pivot point. If it approaches the $5.15 resistance level, significant changes may occur.

Helius Medical Technologies Inc Stock (HSDT) Financials Data

Helius Medical Technologies Inc (HSDT) Revenue 2024

HSDT reported a revenue (TTM) of $792.00 thousand for the quarter ending September 30, 2023, a +3.80% rise year-over-year.

Helius Medical Technologies Inc (HSDT) Net Income 2024

HSDT net income (TTM) was -$12.69 million for the quarter ending September 30, 2023, a +4.49% increase year-over-year.

Helius Medical Technologies Inc (HSDT) Cash Flow 2024

HSDT recorded a free cash flow (TTM) of -$10.55 million for the quarter ending September 30, 2023, a +32.61% increase year-over-year.

Helius Medical Technologies Inc (HSDT) Earnings per Share 2024

HSDT earnings per share (TTM) was -$21.49 for the quarter ending September 30, 2023, a +87.68% growth year-over-year.

Helius Medical Technologies Inc Stock (HSDT) Latest News

Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™

GlobeNewswire Inc.

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire Inc.

Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

GlobeNewswire Inc.

Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients

GlobeNewswire Inc.

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.